Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complications associated with intraperitoneal 32P

M Tharp1, N B Hornback

  • 1Department of Radiation Therapy, Indiana University Medical Center, Indianapolis 46202.

Gynecologic Oncology
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2003
Same author

Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod.

Cutis·2000
Same author

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Proceedings of the National Academy of Sciences of the United States of America·1999
Same author

Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail.

Journal of the American Academy of Dermatology·1998
Same author

Hemorrhagic gastritis due to syphilis. An unusual condition simulating lymphoma.

Journal of the Mississippi State Medical Association·1995
Same author

Synergistic cytotoxic and antitumor effects of irradiation and taxol on human HeLa cervix carcinoma and mouse B16 melanoma cells.

In vivo (Athens, Greece)·1994
Same journal

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026
Same journal

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.

Gynecologic oncology·2026
Same journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same journal

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same journal

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.

Gynecologic oncology·2026
Same journal

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
See all related articles

Intraperitoneal 32P therapy for ovarian cancer can cause acute and chronic complications. Adjunctive radiotherapy significantly increases the risk of severe chronic complications, particularly bowel obstructions.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Nuclear Medicine

Background:

  • Intraperitoneal 32P (radionuclide) therapy is used for ovarian cancer.
  • Complications and risk factors associated with this treatment require evaluation.

Purpose of the Study:

  • To retrospectively review complications of intraperitoneal 32P therapy.
  • To identify factors related to the development of acute and chronic complications.

Main Methods:

  • Retrospective chart review of 95 patients treated with intraperitoneal 32P.
  • Analysis of complication types (mild, moderate, severe) and their correlation with treatment parameters.
  • Follow-up averaged 43.6 months.

Main Results:

Related Experiment Videos

  • 21% of patients experienced acute side effects, primarily mild.
  • 15% experienced chronic complications, with severe cases being bowel obstructions.
  • Acute side effects correlated with instillate volume (P=0.049).
  • Chronic complications were linked to adjunctive pelvic/abdominal radiotherapy (44% vs 17%, P=0.04).

    • Conclusions:

    • Intraperitoneal 32P therapy is associated with manageable acute side effects.
    • Adjunctive radiotherapy significantly increases the risk of severe chronic complications, mainly bowel obstructions.
    • Treatment protocols should consider the combined risks of 32P and radiotherapy.